Last reviewed · How we verify
TBE booster vaccination
TBE booster vaccination stimulates the immune system to produce antibodies and cellular immunity against tick-borne encephalitis virus through repeated antigen exposure.
TBE booster vaccination stimulates the immune system to produce antibodies and cellular immunity against tick-borne encephalitis virus through repeated antigen exposure. Used for Booster vaccination for tick-borne encephalitis (TBE) prevention in previously vaccinated individuals.
At a glance
| Generic name | TBE booster vaccination |
|---|---|
| Also known as | Vaccine: FSME-Immun® (Fruehsommer-Meningoencephalitis), One dose (0.5 ml) contains:, 2.4 micrograms Tick-Borne Encephalitis Virus ( strain Neudoerfl),, adsorbed on aluminium oxide, hydrated (0.35 milligrams Al3+), Manufacturer: Baxter Innovations GmbH |
| Sponsor | Medical University of Vienna |
| Drug class | Inactivated viral vaccine |
| Target | Tick-borne encephalitis virus envelope proteins |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
TBE booster vaccination contains inactivated tick-borne encephalitis virus antigen that triggers both humoral (antibody) and cell-mediated immune responses. Booster doses are administered at intervals to maintain or enhance protective antibody titers against TBE virus infection. This approach ensures sustained immunity against the virus transmitted by infected ticks in endemic regions.
Approved indications
- Booster vaccination for tick-borne encephalitis (TBE) prevention in previously vaccinated individuals
Common side effects
- Injection site pain, redness, or swelling
- Headache
- Myalgia or fatigue
- Low-grade fever
Key clinical trials
- Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules (PHASE4)
- TBE Seropersistence up to 10 Years After First Booster in Adults (PHASE4)
- TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients (PHASE4)
- Application of a TBE-Vaccine in Obese Persons (PHASE4)
- Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401) (PHASE4)
- Vaccine Study for Tick-Borne Encephalitis Virus (TBEV) (PHASE2)
- Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years (PHASE4)
- Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TBE booster vaccination CI brief — competitive landscape report
- TBE booster vaccination updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI